GEN profiled the Laboratory for Advanced Medicine (LAM) and new CEO Kenneth Chahine, PhD, JD, as the company prepared to launch its first liquid biopsy for the early detection of liver cancer.
Featured in GEN — Genetic Engineering & Biotechnology News. By Alex Philippidis.
GEN profiled the Laboratory for Advanced Medicine (LAM) — the company from which Helio would later emerge — as it prepared, under new CEO Kenneth Chahine, PhD, JD, to launch its first liquid biopsy: a blood test designed to detect early-stage liver cancer, with regulatory approvals expected to begin in China.
In the interview, Chahine discussed the company’s sharpened commercial focus, its first liquid biopsy designed to detect liver cancer at the earliest stages, and plans to develop tests for additional cancers.
Read the full profile at GEN — Genetic Engineering & Biotechnology News.
Source: GEN Edge — “At Laboratory for Advanced Medicine, New CEO Sharpens Commercial Focus.”